ADMEcell- New Technology For Transporting Cell Based Assays

Posted by Sandy Koshkin on Thu, Apr 12, 2012 @ 05:08 PM

Ready-to-Use Cell-Based Assays 

The Cell-Based Assay market is projected to continue double digit growth over the next several years. One of the major challenges facing the development and manufacturing of Cell based assay products for drug discovery and development is the difficulty associated with preserving the cells and the integrity of cell junctions during the transportation and storage of the finished kits. There are numerous Cell based assay Kits available such as cell viability and proliferation.  Caco Monolayer

A unique proprietary  shipping medium has been introduced by ADMEcell that allows for selected cell based assay kits to be shipped in a solid state at room temperature.  Once the kits are received, the shipping medium is simply removed by liquefaction at 37oC, and replaced with a fresh medium.  The cells are then ready for use in the assay for experimental compounds soon after.

Cell Based Assays such as Caco-2, MDCK and BCRP benefit from this innovative technology. ADMEcell’s  Ready-To-Use  Cell Based Assay Kits- Ready-to-Use Cell-Based Assays - are shipped at room temperature on a regular basis, providing a unique and convenient tool for accelerating the drug discovery and development process.

As the Cell Based Assay market continues to grow,  availability of a shipping medium that allows for shipping Ready-To-Use Cell Based products  at room temperature will have a major impact on the availability of the kits that would not have been readily available otherwise.

Tags: Ready To Use Assays, Ready To Use Kits, caco-2 assay, cell based assays, Drug Transporter studies

ADMEcell Will Be Exhibiting At The AAPS Meeting Oct 24-27 Booth #1559

Posted by Sandy Koshkin on Thu, Oct 13, 2011 @ 11:50 AM

ADMEcell To Exhibit At The AAPS Meeting IN Washington DC Oct 25-27

ADMEcell will join over 500 exhibitors at the upcoming AAPS meeting in Washinton DC October 25 through October 27.  This is the 25th anniversary of the AAPS meeting which will include speakers such as Janet Woodcock, M.D., director of the Center for Drug EvaluatioAAPS Meetingn and Research at the Food and Drug Administration, who will provide her view on the future of regulations. John Lechleiter, Ph.D., president and chief executive officer, Eli Lilly and Company, will speak to the future shape of the global pharmaceutical industry; Francis S. Collins, M.D., Ph.D., director, U.S. National Institutes of Health, will speak on current research that may lead to new therapies in the future. Sir Michael Rawlins, M.D., chairman of the National Institute of Health & Clinical Excellence (NICE) of the United Kingdom, will speak on the cost benefits of therapies and the societal ability to pay for the therapies, "Value for Money in Healthcare: The Future." NICE is an independent organization responsible for providing national guidance on promoting good health and preventing and treating ill health.

ADMEcell will showcase its three product lines for providing tools for drug discovery and development:

Cell based Assays: Caco-2, MDR-1, BCRP & BBB Permeability

http://www.admecell.com/assays-cellbased/

ELISA Kits For Monoclonal Antibody Assessment: Quantification kits for Human, Mouse, Rat & Bovine IgG and Mouse Ig Isotyping

http://www.admecell.com/assays-elisabased/

Protein Binding Kits For HAS and AGP

http://www.admecell.com/assays-transil/

Please plan to visit us at Exhibit #1559

Tags: transporters, ELISA Kits, Human IgG Kits, Mouse IgG Kits, Rat Igg Kits, Mouse Isotyping Kits, Ready To Use Assays, Ready To Use Kits, aaps meeting, aaps exhibition, caco-2 assay, cell based assays, MDR1 Kits, Protein Binding Kits, Blood Brain Absorption Kits, Caco-2 Kits

DMPK Labs and Integrating New In-Vitro Assays

Posted by Sandy Koshkin on Thu, Aug 04, 2011 @ 04:45 PM

DMPK Labs and Integrating New In Vitro Assays

Improve DMPK Productivity by Using the Industry Leading Solution

Determining the Drug Metabolism and PharmacoKinetic properties of a drug is crucial to understanding its safety and efficacy before the regulatory approval process takes place.

Currently, DMPK Labs have a tremendous balancing act on their hands betweenMDR1 Plated Cells getting all the routine work completed with minimal staff and deciding on handling selected new compounds. Many of these compounds can be tested in house or contracted out to CRO.  Preparing reagents and developing in-house assays require time and resources, whereas waiting for data from an outside source uses very little resources other than money. However, Ready-to-Use Assay Kits offer a simple solution to balance the resources needed and the associated costs.

So, how does a lab begin to evaluate a newer technology such as a new in vitro assay that can be very helpful long term? In the short term, it seems like there is no time available…However, the benefits  for DMPK labs are enormous  if they can dedicate some time to evaluate for example, a Ready-To-Use cell based assay such as Caco-2 or MDCR1 or Plasma Protein Binding to compare the cost and time savings with their current methods. These assays are available at a reasonable price and produce speedy and reliable results to make the life  easier in the DMPK Labs.

http://www.admecell.com/assays-transil/

http://www.admecell.com/assays-cellbased/

http://www.admecell.com/assays-elisabased/

Tags: transporters, ELISA Kits, Human IgG Kits, Mouse IgG Kits, Ready To Use Assays, Ready To Use Kits, caco-2 assay, cell based assays, MDR1 Kits, Protein Binding Kits, Blood Brain Absorption Kits, Caco-2 Assays

Accelerate Your Drug Development Processes By Using Ready To Use Assays

Posted by Sandy Koshkin on Wed, Jul 27, 2011 @ 05:31 PM

Accelerate Your Drug Discovery and Development Processes and Control  Your Data when Evaluating New Drug Compounds by Using Ready-to-Use Assays

State of the art Ready-to-Use Assays-  offered by ADMEcell www.admecell.com eliminate the need for time consuming in-house reagent preparations and assay development, thereby reducing the costs and enhancing the drug discovery and development processes.  ADMEcell’s CacoReady  and PreadyPort-MDR1 Ready To Use ELISA Kitshttp://www.admecell.com/assays-cellbased/ are examples of Ready-to-Use Assay Kits  for generating  permeability data for new drug candidates.  These assays eliminate the need for in-house cell culture production offering  a great deal of cost  and time savings. In addition, you will have control on generating your own data without delays.   ADMEcell also offers a number of Ready-to-Use products with the same benefits for the assessment of Plasma Protein Binding and Blood Brain Absorption of drug candidates http://www.admecell.com/assays-transil/ Finally, ADMEcell ELISA-Based Ready-to-Use Assay Kits http://www.admecell.com/assays-elisabased/ for quantification of IgG from various species and Mouse Ig Isotyping are available for rapidly and conveniently screening of therapeutic antibodies.

Once a biotech company has decided to implement this strategy,  application of the Ready-to-Use Assay Kits will surely become an important part of its long term preclinical development plan.

Tags: ELISA Kits, Human IgG Kits, Mouse IgG Kits, Ready To Use Assays, Ready To Use Kits, MDR1 Kits, Protein Binding Kits, Blood Brain Absorption Kits, Caco-2 Kits, Caco-2 Assays